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Abstract The first biosimilar monoclonal antibody (inf-
liximab, CT-P13) was registered by the European Medi-
cines Agency in 2013 for the treatment of several
inflammatory conditions including rheumatoid arthritis
(RA). Biosimilar infliximab is first being marketed in the
Central and Eastern European countries. This paper pre-
sents the estimated budget impact of the introduction of
biosimilar infliximab in RA over a 3-year time period in six
selected countries, namely Bulgaria, the Czech Republic,
Hungary, Poland, Romania and Slovakia. A prevalence-
based model was constructed for budget impact analysis.
Two scenarios were compared to the reference scenario
(RSc) where no biosimilar infliximab is available: bio-
similar scenario 1 (BSc1), where interchanging the origi-
nator infliximab with biosimilar infliximab is disallowed,
and only patients who start new biological therapy are
allowed to use biosimilar infliximab; as well as biosimilar
scenario 2 (BSc2), where interchanging the originator
infliximab with biosimilar infliximab is allowed, and 80 %
of patients treated with originator infliximab are inter-
changed to biosimilar infliximab. Compared to the RSc, the
net savings are estimated to be €15.3 or €20.8 M in BSc1
and BSc2, respectively, over the 3 years. If budget savings
were spent on reimbursement of additional biosimilar inf-
liximab treatment, approximately 1,200 or 1,800 more
patients could be treated in the six countries within 3 years
in the two biosimilar scenarios, respectively. The actual
saving is most sensitive to the assumption of the acquisi-
tion cost of the biosimilar drug and to the initial number of
patients treated with biological therapy. The study focused
on one indication (RA) and demonstrated that the intro-
duction of biosimilar infliximab can lead to substantial
budget savings in health care budgets. Further savings are
expected for other indications where biosimilar medicines
are implemented.
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Introduction
Chronic inflammatory conditions, such as different types of
autoimmune arthritis, inflammatory bowel diseases and
psoriasis, lead to considerable functional disability, a
lowered quality of life and work capacity, as well as sig-
nificant economic burden on the patients, families and
society. Biological drugs developed over the recent dec-
ades provided new, highly effective, but very costly treat-
ment options [1]. The high price created a barrier to access
for patients in the Central and Eastern European (CEE)
region, and the utilization of biological drugs is still lower
compared to high income countries [2]. Access to biolog-
ical drugs varies greatly within the CEE as well.
In September 2013, a biosimilar monoclonal antibody
(mAb), infliximab (CT-P13) received market authorisa-
tion in Europe for the treatment of adult patients with
rheumatoid arthritis (RA), ankylosing spondylitis,
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psoriatic arthritis, psoriasis, adult and pediatric ulcera-
tive colitis, and Crohn’s disease. It is expected that the
spread of biosimilar mAbs will lead to cost savings in
health care budgets, and might also improve the access
to biological therapies. However, the potential savings
have not yet been studied. This study aimed to analyse
the budget impact implied by the introduction of bio-
similar infliximab for the treatment of RA in six selected
CEE countries, namely Bulgaria, Czech Republic, Hun-
gary, Poland, Romania and Slovakia. RA was selected to
estimate the budget impact, as this indication involves
the largest number of patients treated with biological
agents.
Budget impact analysis (BIA) is used to estimate the
financial consequences of adoption and diffusion of a new
health intervention within a specific health care setting or
system context [3–5]. Besides cost-effectiveness analysis
(CEA), BIA is required as part of the application dossiers
of all new pharmaceuticals seeking public funding in the
CEE, similar to a number of other countries. However,
despite the importance of BIA, there is a shortage of lit-
erature in this field compared to the large number of CEAs.
In a systematic literature review by Orlewska et al. [4],
altogether 34 BIAs were identified in peer-reviewed jour-
nals, irrespective of therapy type and geographical region.
In a recent systematic literature review by van de Vooren
et al. [5], 17 BIA publications focusing on European
countries were identified. Furthermore, both reviews
pointed out that several studies fail to reach appropriate
methodological quality. Amongst the publications included
in these reviews, only two BIAs dealt with biological
treatments, both in RA [6, 7] and none of these studies was
conducted in the CEE region. No studies that focus on the
expected budget impact of biosimilar drugs have been
published so far.
It is rather challenging to estimate the budget impact of
a new biosimilar mAb drug in the CEE region for several
reasons. First, data on current, available biological treat-
ments (price and patient populations, practice of current
biological use) are not always available or reliable for all
CEE countries. Patient registries are scarce in CEE; thus
our knowledge is limited regarding size, disease severity
and other characteristics of patients currently using bio-
logical drugs, as well as the pattern of biological treatment
in this region. Second, we have to rely on assumptions
regarding the future use of a biosimilar drug (market share,
interchanging or switching of biological therapies).
Thus, in this paper we estimated cost savings from the
payer’s perspective in six CEE countries, considering two
extreme biosimilar scenarios (BScs), depending on whether
interchanging a biosimilar is allowed or not, compared to
the reference scenario (RSc) where no biosimilar inflix-
imab is available.
Methods
This BIA estimated the impact of biosimilar infliximab on
the healthcare budget over a 3-year time frame in six CEE
countries. The model was constructed in compliance with
the principles of good practice for BIA from the Interna-
tional Society for Pharmacoeconomics and Outcomes
Research (ISPOR) [3]. The perspective of analysis was that
of a third party payer.
Modelling framework
A prevalence-based, country-specific budget impact model
was developed for RA. The budget impact model evaluated
the impact of introducing biosimilar infliximab into the
current treatment mix of biological drugs available for the
treatment of RA in the six countries by comparing total
costs (drug, administration and monitoring) of scenarios
where biosimilar infliximab is introduced (BSc1 and BSc2)
to the total costs of the RSc (where no biosimilar agent is
available). Since there is a great uncertainty in policy
discussions around interchanging originator infliximab
with biosimilar infliximab (see the paper of To´thfalusi et al.
[8] in this supplement) we decided to explore the budget
impact in two extreme scenarios:
Biosimilar scenario 1 (BSc1) Interchanging originator
infliximab with biosimilar infliximab is disallowed. Only
patients who start a new biological therapy are allowed
to use biosimilar infliximab.
Biosimilar scenario 2 (BSc2) Interchanging of originator
infliximab with biosimilar infliximab is allowed after
6 months from treatment start, and originator infliximab
is interchanged by biosimilar infliximab in 80 % of
patients. Also patients who start a new biological therapy
are allowed to receive biosimilar infliximab as first-line
therapy.
The model tracked the movement of patients between
different biological treatments. At the end of each model
cycle, patients could either remain on the original treat-
ment, or switch to another biological treatment, or leave
the model (switch to a conventional synthetic disease
modifying antirheumatic drug [csDMARD] therapy). The
model functioned in quarter-year time cycles according to a
3-month-long evaluation period. The number of RA
patients treated with biological agents in any quarter year
was the sum of the population in the previous quarter year
and the estimated growth. The number of patients starting
new biologic treatment (first drug or switch) was the sum
of discontinuations from all causes in the previous quarter
year and the estimated growth. New patients receiving
biological drugs exactly compensated for patients exiting
the model.
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Total costs of scenarios were estimated as the aggre-
gation of the product of patients in different model states
and costs associated with these states. Incremental costs
were calculated as the difference of BScs (BSc1 and BSc2)
and RSc. Cost savings are reported in 2013 prices; no
discounting was applied. Besides cost savings in monetary
terms, we also provide estimations for gains in terms of
possible number of new patients who could be treated
additionally if the savings were reinvested in additional
biosimilar infliximab treatment.
Patient population
The size of initial populations (Table 1) in both the reference
(RSc) and the two BScs (BSc1 and Bsc2) were set on the
basis of real 2013 penetration data in the six CEE countries
(i.e. the number of patients with RA treated with different
biological drugs in 2013). The number of RA patients in the
six countries treated with abatacept, adalimumab, certo-
lizumab, etanercept, golimumab, infliximab, rituximab and
tocilizumab were 153, 4,055, 1,376, 4,197, 860, 1,643, 3,098
and 1,944, respectively [9]. The model also accounted for the
possibility of patient number expansion. A future growth rate
of treated patients was assumed to predict the number of
treated patients over the 3 years. Also, budget impact esti-
mates included calculations on the numbers of previously
untreated patients who started new biological drugs. We
made no restriction on the number of potential patients. We
only assumed that growth in the number of patients treated
with biological drug would not exceed the number of patients
eligible for biological therapy on a 3-year time horizon.
Costs associated with model states
Only direct costs of the drug treatment were considered,
including the acquisition costs of drugs, the cost of
administration and the cost of treatment-related monitoring
(laboratory test, rheumatology visits, X-ray, cardiology and
pulmonology monitoring). The model accounted for those
biological agents that are reimbursed in a given country for
the treatment of RA (Table 2).
Drug acquisition costs were derived from official
national price lists in each country. We used retail prices
for the analysis. Retail price of biosimilar infliximab was
assumed as 75 % of originator infliximab in all six coun-
tries. Drug acquisition costs were calculated on a quarterly
basis for both the induction and maintenance periods for
each drug (Table 3). The doses and administration sched-
ules for each biological agent were those provided by the
European Medicines Agency summaries of product char-
acteristics. The calculation took into account both induc-
tion and maintenance dosing schedule in the case of
infliximab, certolizumab and abatacept. For these drugs,
different dosing schedules were used in the first and the
subsequent quarter after starting the treatment. Further-
more, the dosage of some biological drugs (infliximab,
abatacept and tocilizumab) depends on body weight. The
average body weight of an RA patient was estimated at
75 kg (SD17), based on Hungarian survey among patients
treated with infliximab [10]. If a full package is not used
for one patient, the rest of the dosage might or might not be
used for others. The latter is considered as waste. We
assumed that the rest of a dosages was administered to the
next patient.




Average body weight in RA (kg) 75 NHIFA
2010
Initial population on biologic in RA 17,257 Pe´ntek et al.
[9]
Three months discontinuation




Biologic market yearly growth rate 10 % Assumption
Biosimilar infliximab price in % of
originator infliximab price
75 % Assumption
Distribution of switches from TNF-inhibitor to
Another TNF inhibitor 60 % NHIFA
2013 [12]
Abatacept 0 % NHIFA
2013 [12]
Rituximab 7 % NHIFA
2013 [12]
Tocilizumab 33 % NHIFA
2013 [12]
Distribution of switches from tocilizumab to
Another TNF inhibitor 89 % NHIFA
2013 [12]
Rituximab 10 % NHIFA
2013 [12]
Probability of switches from rituximab to




Rate of interchanging by the
physicians*
0–80 % Assumption
Probability of initiating biosimilar
infliximab instead of starting
originator infliximab
65 % Assumption
Probability of initiating biosimilar
infliximab instead of starting non-
infliximab TNF-inhibitor
20 % Assumption
*Interchanging rate: the given rate is reached at the end of the first
year applying a linear growth
NHIFA National Health Insurance Fund Administration
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Monitoring and administration costs were estimated
according to clinical guidelines. Tariffs from the National
Health Insurance Fund Administrations (NHIFA) were
used to assess monitoring (outpatient visits, lab tests,
imaging) and administration (visits to nurse, outpatients
visit) costs. In the case of unavailable price data in a
country, Hungarian tariffs were converted to estimate these
costs.
Assumptions in model
Movements between model states
Based on the results of a previous review [11], we assumed
that the 3-month discontinuation probability is 0.049 % for
all treatments. The probabilities that a given biological
drug will be selected as second-line treatment are presented
in Table 1. These rates were derived from the Hungarian
NHIFA database [10] and were applied to each of the six
countries.
Infliximab biosimilar as first-line and second-line treatment
We assumed that in 65 % of the cases when originator
infliximab would have been selected as a first-line or sec-
ond-line treatment, the physician would prescribe biosim-
ilar infliximab. Also, an assumption was made that in 25 %
of the cases when a non-infliximab tumour necrosis factor
inhibitor (TNF-inhibitor, namely adalimumab, certo-
lizumab, etanercept and golimumab) would have been
selected as a first-line or second-line treatment, the physi-
cian would prescribe biosimilar infliximab (linearly
reaching these percentages until the end of the first year,
and remaining until the end of the third year).
Interchanging
The rate of interchanging originator infliximab treatment
with biosimilar infliximab treatment is 0 % in BSc1 and
80 % in BSc2 (linearly reaching 80 % until the end of the
first year, and remaining until the end of the third year).
BSc1, when interchangeability is not allowed at all, is the
Table 2 Retail prices of biological treatments in €
Brand name Substance Retail price (EUR)
BUL CZE HUN POL ROM SLO
ORENCIA 1 9 250 Abatacept NR 420 342 NR 352 395
HUMIRA 2 9 40 Adalimumab 1,262 1,006 957 1,056 1,037 1,119
CIMZIA 2 9 200 Certolizumab 1,093 975 957 NR 931 1,043
ENBREL 4 9 50 Etanercept 1,164 1,021 957 1,015 968 1,048
SIMPONI 1 9 50 Golimumab 1,282 1,112 1,109 NR 1,067 1,646
REMICADE 1 9 100 Infliximab NR 609 534 537 481 617
MABTHERA 1 9 500 Rituximab 1,255 1,275 1,257 1,553 1,309 1,406
ROACTEMRA 400 Tocilizumab 1,255 846 728 NR 745 778
ROACTEMRA 200 Tocilizumab 948 423 366 NR 380 411
ROACTEMRA 80 Tocilizumab 479 169 148 NR 161 167
Sources: SLO: http://www.adcc.sk; BUL: National Health Insaurance Fund, Cgbc]r c kerapcnda, robno HPOR pagkaoagopelayaHapel,a § 10
on 24 vapn 2009u. payckodbzna b pelapapagkaoayeyakerapcndeybgpolyrnbgoxk. 262, ak.4, n.1 onParoyapakerapcndeybnegpolyrnb d http://
www.nhif.bg; CZE: State Institute for Drug Control, http://www.sukl.eu/; HUN: National Health Insaurance Fund www.oep.hu; POL: Ministry
of Health, http://www.mz.gov.pl/; ROM: Ministry of Health, http://www.msf-dgf.roCatalogul National al preturil or medicamentel or de
uzumanautorizate de punerepepiata—Ianuarie 2012
NR not reimbursed, BUL Bulgaria, CZE Czech Republic, HUN Hungary, POL Poland, ROM Romania, SLO Slovakia
Table 3 Quarterly drug costs in
rheumatoid arthritis, in euros
Q quarter year, Inf original
infliximab, Adl adalimumab, Crt
certolizumab, Etn etanercept,
Glm golimumab, Abt abatacept,
Rtx rituximab, Tcl tocilizumab
Country Inf Adl Crt Etn Glm Abt Rtx Tcl
Q1 Q2 Qi Qi Q1 Qi Qi Qi Qi Qi Qi
Bulgaria 3,696 2,156 2,002 4,100 5,192 3,553 3,784 3,847 – 2,509 6,117
Czech R. 4,130 2,409 2,237 3,283 4,650 3,182 3,333 3,349 3,948 2,560 4,142
Hungary 3,695 2,155 2,001 3,189 4,660 3,189 3,189 3,411 3,280 2,577 3,639
Poland 3,721 2,170 2,015 3,522 – – 3,387 – – 3,188 –
Romania 3,273 1,909 1,773 3,395 4,455 3,048 3,171 3,226 3,325 2,638 3,659
Slovakia 4,168 2,431 2,258 3,635 4,953 3,389 3,407 4,937 3,702 2,811 3,795
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strictest possible option, while BSc2 is a potential extreme
case, with 80 % replacement of originator by biosimilar
(e.g., in an extreme situation where the payer would oblige
providers to replace the originator treatment).
Sensitivity analysis
One-way sensitivity analysis was performed by changing
different parameters of the model by ±10 %: the
assumption on the acquisition cost of biosimilar infliximab,
the size of the initial population and its growth rate over
time, the discontinuation rates of biological drugs, and the
rate of interchanging infliximab with biosimilar infliximab.
Results
Results of the analysis are presented in Table 4. In 2013,
approximately 17,300 RA patients were treated with bio-
logical drugs in the six CEE countries. Findings show that
in BSc1 the introduction of biosimilar infliximab in the
biologic treatment setting led to a total savings of €15.3 M
in the first 3 years of its introduction. Allowing for inter-
changing original infliximab with biosimilar infliximab had
a significant impact on budget savings. In BSc2, the total
saving was estimated to be €20.8 M over the 3 years.
The cost savings may be reinvested to treat more
patients with biological drugs. If all budget savings were
spent on reimbursing biological therapy of new patients
with biosimilar infliximab, an additional 1,205 patients in
BSc1 or 1,790 patients in BSc2 could be treated with
biological drugs after 3 years. According to the results of
the sensitivity analysis, the number of the initial population
treated with biological agents and the assumption on the
acquisition cost of the biosimilar were the two main cost
drivers (20.1 and 18.6 %) in the model (Fig. 1).
Discussion
This is the first study to attempt to estimate the budget
impact of introducing the first biosimilar mAb (infliximab)
in the CEE countries. The analysis was carried out with
multiple scenarios in order to evaluate various
assumptions.
Our analysis shows that introducing biosimilar inflix-
imab as a treatment for RA might result in considerable
budget savings. We demonstrated that the potential budget
savings for the six countries are €0.9, €4.8 and €15.3
million in the first, second and third year of implementation
in the strictest scenario (Bsc1), where the interchange from
originator infliximab to biosimilar infliximab is not
allowed.
Allowing for the interchange from original infliximab to
biosimilar infliximab (BSc2) resulted in even more savings
compared to the no-interchanging scenario (BSc1). This
increase was driven by a faster reduction of patient number
on the more expensive originator infliximab. The one-way
sensitivity analysis revealed that it was the acquisition
price of biosimilar infliximab that had the greatest impact
on budget savings. In contrast, the yearly growth rate of the
total number of patients treated with biological agents had
only a minor effect.
If the budget savings were reinvested in the treatment of
additional patients with biosimilar infliximab, 1,205 and
1,790 additional RA patients could be treated in the two
BScs, respectively. Thus, the implementation of biosimilar
treatment may significantly improve access to biological
therapy in the CEE countries. As mentioned in the intro-
duction, the utilization of biological drugs is significantly
lower in the CEE countries compared to high-income
countries [2]. For example, in the review by Laires et al.
[2], the average access rate to biological treatment amongst
RA patients was an average of 19.1 % in 15 Western and
Southern European countries. In contrast, according to our
estimations, the average access rate in the six CEE coun-
tries was about 5.3 %. Therefore, additional access to
biologicals in these countries is particularly precious.
In recently published reviews [4, 5], two budget impact
analyses [6, 7] were identified in RA. Budget impacts
calculated in our study can hardly be compared directly
with the findings of these analyses of biological treatments,
due to differences in settings and jurisdictions. However,
comparison of relevant findings and conclusions might be
Table 4 Results of the scenario analyses
Budget impact (€) Number of new RA patients on biological treatment if
budget savings would be spent on biosimilar infliximab
Year 1 Year 2 Year 3 Total Year 1 Year 2 Year 3
Biosimilar scenario 1 -945,241 -4,782,462 -9,612,331 -15,340,034 165 672 1,205
Biosimilar scenario 2 -2,394,545 -6,968,620 -11,463,059 -20,826,224 242 1,002 1,790
Biosimilar scenario1: interchanging of biosimilar and original biologicals is not allowed
Biosimilar scenario2: interchanging of biosimilar and original biologicals is allowed at least 6 months after treatment start
Budget impact analysis of biosimilar infliximab S69
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meaningful. Launois et al. [6] studied the budget impact
initiated by the introduction of rituximab after failure of a
TNF-inhibitor therapy from the perspective of the French
health care system. They estimated a total savings of
€88 M (23 %) over 4 years, deriving mainly from lower
drug costs. The yearly acquisition cost of rituximab was
57 % of the average acquisition costs of TNF-inhibitors. In
comparison, in our model, the yearly acquisition cost of
biosimilar infliximab was assumed to be 75 % of the
originator costs. In both analyses, budget savings were
most sensitive to the changes in drug acquisition costs.
Both studies similarly conclude that the implementation of
biological agents with lower prices might lead to notable
cost savings. In an earlier (2002) study by Sørensen and
colleagues, the implementation of etanercept and inflix-
imab in the Danish health care system was analysed. The
setting of this study was considerably different from ours.
The reference case was csDMARD therapy, which might
result in significantly higher incremental costs than in our
reference case. Sørensen and colleagues reported a €113 M
and a €321 M budget increase over 3 years, assuming a
modest or a progressive market growth. They highlighted
the financial challenges that these new treatment regimens
will pose on healthcare systems when they are introduced.
Limitations
Due to the number of limitations of this BIA, the results
should be interpreted with caution. First, it should be taken
into account that any model is a simplification of the real
treatment process. The model collected only resource use
and costs for an average patient, and did not consider other
factors such as disease severity, patient characteristics or
other disease-related factors. The model did not account for
the changes in indirect societal costs arising from absence
from work. Another limitation is that a dynamic cohort
approach was applied in the study, since in each model
cycle, some patients left the model while new patients
entered it. Yet, we were interested in the total budget impact
for the whole population rather than in the individual patient
patterns. Also, the model did not account for the potential
decrease in future drug costs (neither for biosimilar nor
originator). However, it is possible that drug prices will
decrease in the future due to increased market competition
and the increased number of patients treated with biological
agents. This might also lead to budget savings.
Furthermore, the sensitivity analysis showed that the
results are highly sensitive to changes in model parameters.
Several assumptions were made regarding the practice of
available biological therapies based on data available from
previous literature or from registers (e.g., discontinuation,
switch). Since these data are not always available or reli-
able for every CEE country, we made a great simplification
that discontinuation rates and probabilities of taking up a
given treatment are equal in each of the six countries.
Our assumptions about the future use of biosimilar inf-
liximab (market share, interchanging or switching of bio-
logical therapies of the current biological) are even more
uncertain due to the lack of empirical data on the use and
experience with biosimilar treatments (interchangeability,
market growth). However, these parameters were tested in
the sensitivity analysis.
Conclusions
Based on the present analysis, the introduction of biosim-
ilar infliximab as an alternative treatment option for RA in
Fig. 1 One-way sensitivity analysis results. Variables included in the
one-way sensitivity analysis are listed on the vertical axis. The bars
represent the budget impacts with the lowest and highest values of the
given variable. The variables are ordered so that the widest budget
impact interval appears at the top of the figure, the next largest
appears second from the top, and so on
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CEE is predicted to bring substantial cost savings to the
national health care budget. The main drivers of budget
savings were the current population treated with biological
agent and the price of the new drug. Allowing interchange
between biosimilar and originator biological drug might
have substantial favourable effect on budget savings. Based
on these results, the use of biosimilar infliximab appears to
be economically attractive, because it offers the potential to
reduce the total expenditures or to increase the number of
patients treated with biologicals.
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